Kura Oncology announces new U.S., European patents for tipifarnib
Kura Oncology announced that the U.S. Patent and Trademark Office has issued and the European Patent Office has granted new patents further protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase inhibitor. Tipifarnib is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma. The newly issued U.S. patents are as follows: U.S. Patent No. 10,335,404 includes multiple claims directed to a method of treating patients with HRAS mutant HNSCC consisting of administering any farnesyl transferase inhibitor; and U.S. Patent No. 10,292,979 includes multiple claims directed to the use of tipifarnib as a method of treating patients with HRAS mutant non-small cell lung carcinoma. In addition, the newly granted European patent is as follows: European Patent No. 3277842 includes multiple claims directed to the use of tipifarnib as a method of treating patients with HRAS mutant HNSCC. Each of the patents has an expiration date of August 2036, excluding any possible patent term extension.